Boothbay Fund Management’s Akebia Therapeutics AKBA Stock Holding History

Boothbay Fund Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-246,300	Closed	-$177K	–	2214
2022 Q1	$177K	Buy	246,300 +230,477	+1,457%	+$493K	﹤0.01%	1931
2021 Q4	$36K	Sell	15,823 -59,417	-79%	-$162K	﹤0.01%	1789
2021 Q3	$217K	Buy	75,240 +24,468	+48%	+$69.9K	0.01%	1521
2021 Q2	$192K	Buy	50,772 +16,470	+48%	+$55.4K	0.01%	1541
2021 Q1	$116K	Buy	34,302 +14,970	+77%	+$53.9K	﹤0.01%	1459
2020 Q4	$54K	Sell	19,332 -1,288	-6%	-$3.76K	﹤0.01%	1193
2020 Q3	$52K	Buy	+20,620	New	+$181K	﹤0.01%	1001
2019 Q4	–	Sell	-71,000	Closed	-$278K	–	833
2019 Q3	$278K	Buy	+71,000	New	+$304K	0.03%	593
2019 Q2	–	Sell	-104,000	Closed	-$852K	–	717
2019 Q1	$852K	Buy	104,000 +38,148	+58%	+$262K	0.08%	261
2018 Q4	$364K	Buy	+65,852	New	+$515K	0.05%	346

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Boothbay Fund Management's AKBA Position: Q2 2022 in Review

Boothbay Fund Management sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 246,300 shares — an estimated $177K sold.

Boothbay Fund Management first reported a position in AKBA in Q4 2018 and held it in 10 quarters. The position peaked at $852K in Q1 2019. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

Boothbay Fund Management reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
Boothbay Fund Management sold 246,300 Akebia Therapeutics shares in Q2 2022, an estimated $177K.
Boothbay Fund Management first reported a position in Akebia Therapeutics in Q4 2018 and held it in 10 quarters.
Boothbay Fund Management's Akebia Therapeutics position peaked at $852K in Q1 2019.
96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.